A combinação glucosamina com condroitina mostra-se ineficaz em mais um estudo para artrose de joelhos.
Em mais um estudo randomizado duplo-cego a combinação GS/CH mostrou-se impotente para controlar sintomas e evolução da gonartrose. Esta já era nossa experiência clínica de muitos anos. O combo parece funcionar bem em artrose de mãos, pequenas articulações, não em grandes articulações. Abaixo o Abstract deste estudo feito na Espanha, em que ficou claramente demonstrada a superioridade do placebo.
Objective: To assess the efficacy and safety of chondroitin sulfate (CS) plus glucosamine sulfate (GS) compared to placebo in patients with symptomatic knee osteoarthritis (KOA).
Methods: A multicenter, randomized, double-blinded, placebo-controlled study was performed in 164 patients with Kellgren-Lawrence stages II-III KOA and moderate to severe pain (VAS: 62.1±11.3 mm). Patients were randomized to receive either CS (1200 mg) plus GS (1500 mg) or placebo in a single oral daily dose for 6 months. The mean change in VAS global pain was set as primary endpoint. Secondary outcomes included the mean change in the investigator global assessment, total WOMAC, pain and function subscales of WOMAC, OMERACT-OARSI 2004 responder rate, and rescue medication use. Adverse events were also recorded. A Data and Safety Monitoring Board was constituted to ensure patient safety and data accuracy.
Results: Intriguingly, CS+GS was inferior to placebo in reduction of joint pain for the modified intention-to-treat (mITT) population [11.8±2.4 mm (19%) vs 20.5±2.4 mm (33%); Δ= -8.7; -14.2%; p<0.03], but not for per-protocol completers. Placebo and CS+GS similarly improved total WOMAC, as well as pain and function WOMAC subscales in both mITT population and per-protocol completers. Neither the OMERACT-OARSI responder rate nor the use of rescue medication differed between both groups. Severe adverse events were uncommon and equally distributed.
Conclusion: CS+GS failed to demonstrate superiority over placebo in reducing pain and function impairment in patients with symptomatic KOA at 6 months. Further research may contribute to fully elucidate the suitability of CS+GS combination as therapy in OA. This article is protected by copyright. All rights reserved.